Conference Coverage

VIDEO: Herpes zoster vaccination: Is it safe for rheumatology patients over age 30 on biologics?


 

AT ACR 2014

References

BOSTON– The herpes zoster vaccine may be safe to give to patients who are taking biologic therapies and have quiescent rheumatologic disorders, based on preliminary data from two studies presented at the annual meeting of the American College of Rheumatology.

Dr. Jeffrey Curtis of the University of Alabama at Birmingham presented data about the extent of the increased risk for herpes zoster in rheumatology patients, especially those with systemic lupus erythematosus, and some intriguing results on 630 patients on biologic therapies who inadvertently got the vaccine.

Dr. Stephen Lindsey of Ochsner Health System in Baton Rouge, La., said that he continues to evolve a protocol for herpes zoster vaccination of his patients with rheumatologic disorders.

In our exclusive interview at ACR14, the two researchers discussed the implications of their separate studies on the subject and revealed the next steps of a prospective study of herpes zoster vaccination in patients with rheumatologic disorders that is just getting underway.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

mdales@frontlinemedcom.com

Recommended Reading

Later transplant for renal failure in lupus nephritis may raise graft failure risk
MDedge Rheumatology
Uncertainty remains over importance of subtle hydroxychloroquine eye changes
MDedge Rheumatology
Look to presentation, not pathology, for dermatomyositis diagnosis
MDedge Rheumatology
Three years of prednisone can trigger cataracts in lupus patients
MDedge Rheumatology
Inflammatory rheumatic diseases raise venous thromboembolism risk
MDedge Rheumatology
Nintedanib, pirfenidone approved for pulmonary fibrosis
MDedge Rheumatology
VIDEO: A practical protocol for monitoring discoid lupus
MDedge Rheumatology
Trial backs rituximab for maintenance of ANCA-associated vasculitis remission
MDedge Rheumatology
Multitarget induction therapy superior over short term for lupus nephritis
MDedge Rheumatology
Evidence builds for importance of CVD, new drug targets at ACR
MDedge Rheumatology